Ovoca Bio PLC OVB-GB:London Stock Exchange

RT Quote | Exchange | GBp
Last | 05/02/24 BST
0.75UNCH (UNCH)
52 week range
0.45 - 14.80
Loading...
  • Open0.75
  • Day High0.00
  • Day Low0.00
  • Prev Close0.75
  • 52 Week High14.80
  • 52 Week High Date08/29/23
  • 52 Week Low0.45
  • 52 Week Low Date04/10/24

Key Stats

  • Market Cap839,192.25
  • Shares Out81.56M
  • 10 Day Average Volume134,873.6
  • Dividend-
  • Dividend Yield-
  • Beta1.28
  • YTD % Change-16.67

KEY STATS

  • Open0.75
  • Day High0.00
  • Day Low0.00
  • Prev Close0.75
  • 52 Week High14.80
  • 52 Week High Date08/29/23
  • 52 Week Low0.45
  • 52 Week Low Date04/10/24
  • Market Cap839,192.25
  • Shares Out81.56M
  • 10 Day Average Volume134,873.6
  • Dividend-
  • Dividend Yield-
  • Beta1.28
  • YTD % Change-16.67

RATIOS/PROFITABILITY

  • EPS (TTM)-2.46
  • P/E (TTM)-0.30
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ovoca Bio PLC

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Ovoca Bio PLC is a clinical-stage biopharmaceutical company focused on women’s health. The Company is developing Orenetide, a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women’s health and identifying novel candidates in areas of high unmet medical need. The Company’s lead product, Orenetide (BP-101), is a novel synthetic peptide for the treatment of HSDD and is conveniently administered through a nasal...
Kirill Golovanov
Interim Chairman, Chief Executive Officer, Executive Director
Dmitriy Nikitashenko
Vice President - Finance
Address
17 Pembroke Street, Upper
Dublin
D02 AT22
Ireland